8 in 8: Update on Immunotherapy for Resectable Lung Cancer

The future of chemo-immunotherapy in resectable non-small cell lung cancerПодробнее

The impact of durvalumab for resectable non-small cell lung cancerПодробнее

Expert report on neoadjuvant immune checkpoint inhibitors for NSCLCПодробнее

Updates in immunotherapy for lung cancer at WCLC 2024Подробнее

Outcomes and pCR after chemo-immunotherapy in resectable NSCLCПодробнее

Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC?Подробнее

Adherence & outcomes of neoadjuvant immunotherapy in resectable NSCLCПодробнее

Updates on Immunotherapy for Lung Cancer PatientsПодробнее

Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelinesПодробнее

Medical Oncology Updates for Lung CancerПодробнее

Ep 8: Lung Cancer & ImmunotherapyПодробнее

STS Webinar: Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLCПодробнее

Advances in Immunotherapy & Resectable Non-Small Cell Lung CancerПодробнее

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLCПодробнее

Neoadjuvant Nivolumab in Resectable Lung Cancer | NEJMПодробнее

Neoadjuvant, Adjuvant, or Both: Individualized Perioperative Immunotherapy in Resectable NSCLCПодробнее

Elevating Care in Resectable Stage I-III NSCLCПодробнее

2021 West Oncology | Lung Cancer | Updates on Immunotherapy and Small Cell Lung Cancer Stage 4Подробнее

Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLCПодробнее